Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
264.95
-2.035 (-0.76%)
Market Cap: 35.37 Bil
Enterprise Value: 33.64 Bil
PE Ratio: 72.39
PB Ratio: 32.87
GF Score: 74/100 Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 13, 2026 / 05:40PM GMT
Release Date Price:
$291.48
(-0.19%)
Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst
The healthcare conference, good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam Pharmaceuticals. Sitting up here on stage with me is Jeff Poulton, who is, of course, Chief Financial Officer. Jeff, welcome back to Las Vegas. Thanks for making the trip.
Jeffrey Poulton
Alnylam Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President
No, I always make the trip to Vegas. I'm always here for this one. So I appreciate the invite.
Questions & Answers
Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst
Yeah. We have to continue the tradition. So maybe we can start off with a quick overview of the company in case anyone in the room isn't as familiar with Alnylam and its platform.
Jeffrey Poulton
Alnylam Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President
Yeah. I
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot